SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Bio Technology General - BTGC
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: yosi s who wrote (1953)12/28/1999 11:40:00 PM
From: Slugger  Read Replies (1) of 2028
 
Received my quarterly report yesterday and noticed a few other positives besides the Teva deal. They are as follows:

1)"BTGC has been informed by the government of Israel that it will qualify for significant future tax benefits over the next several years associated with the relocation of its manufacturing facility to larger GMP-designed premises, currently under construction in Israel."

2)Although sales of Oxandrin will be lower for the remainder of this fiscal year the "healthy growth of prescriptions and end user sales should translate into growth in sales" once Olsten completes inventory reduction at the end of this year.

3)Starting a phase II study for it's BioHy product for treatment of pain associated with osteoarthritis of the knee (market is $400 mil and is expected to grow with aging population). They expect to complete the trial in the first half of 2000.

4)(The following has been posted here before.) Ranked 36th among New Jersey Technology Fast 50 and featured in Forbes 200 hot small companies.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News